PURPLE BIOTECH
Sector: Healthcare & Life Sciences
About PURPLE BIOTECH
are committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance.
Products
CAPTN-3
IM1240 is the lead trispecific antibody in development of CAPTN-3, our conditionally-activated tri-specific antibody platform which engages both T cells and NK cells and TAA. IM1240 targets 5T4 as TAA (capped CD3x5T4xNKG2A)
CM24
CM24 is a first-in-class, clinical-stage immune checkpoint inhibitor mAb targeting CEACAM1, with significant potential to treat multiple cancers.
NT219
NT219 is a first-in-class, novel small molecule targeting both IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.
Latest Company Updates
- Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
- CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
- Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
- CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
- Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup